Rich Upton

Rich Upton has worked in the venture capital and healthcare industries since 1999. In 2006, they became a Board Director for Home Diagnostics, Inc., a publicly-traded diabetes management company that was sold to Nipro Corporation in March 2010. In 2008, they became a General Partner at Harbor Light Captial Partners, a venture capital fund focused on early-stage technology and healthcare companies located in the US. In 2009, they became a Board Director for Eggrock, Inc., a private manufacturer of factory-built bathroom pods which was sold to KHS&S Contractors, Inc. in December 2010. In 2010, they became a Board Director for Courtagen Life Sciences, Inc. In 2011, they became a Board Director for Carmell Therapeutics, a private company developing innovative Plasma-based Bioactive Materials (PBMs) to accelerate bone and soft tissue healing. In 2012, they became a Board Director for Alcyone Therapeutics Inc., a private company developing breakthrough technologies to treat complex neurological conditions. In 2017, they became a Portfolio Manager for Harbor Light Alternatives Fund and a Board Director for Medicinal Genomics Corporation, a private company developing technologies that help growers, dispensaries, and testing laboratories ensure patients and consumers have access to safe, quality cannabis. In 2018, they became the Chairman of the Board for Anuncia Medical, Inc., a private company developing and commercializing innovative technologies for hydrocephalus patients.

Rich Upton received their MBA from the University of Virginia Darden School of Business in 1993, their BA in Economics & English from Amherst College in 1988, and attended Phillips Exeter Academy from 1982 to 1983.